

CATABASIS PHARMACEUTICALS, INC.
ONE KENDALL SQUARE
BUILDING 1400E, SUITE B14202
CAMBRIDGE, MA 02139

May 21, 2019

Via EDGAR

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Re: Catabasis Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-231441
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Catabasis Pharmaceuticals, Inc. (the “**Registrant**”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-231441), as amended (the “**Registration Statement**”), so that it may become effective at 9:00 a.m. Eastern time on May 23, 2019, or as soon thereafter as practicable.

Very truly yours,

Catabasis Pharmaceuticals, Inc.

By: /s/ Jill C. Milne
Name: Jill C. Milne
Title: President and Chief Executive Officer
